Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Bone Biologics : Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation

share with twitter share with LinkedIn share with facebook
01/07/2020 | 02:09pm EDT

Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for spine fusion, trauma and osteoporosis markets, has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. In addition, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.

“The results of this Pivotal animal study provide a promising view of the potential of rhNELL-1 and we look forward to advancing the NELL spine program into clinical trials,” said Jeff Frelick, Chief Executive Officer of Bone Biologics.

“In its second clinically relevant sheep study, rhNELL-1 demonstrated increases in fusion and quantity of bone compared to the control,” said Dr. Bill Walsh, Professor and Director, Surgical and Orthopedic Research Laboratories (SORL), UNSW Sydney.

Bone Biologics previously announced that it received Human Research Ethics Committee (HREC) approval for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The pilot study will evaluate the safety and effectiveness of NB1 in adult subjects with degenerative disc disease (DDD) at one level from L2-S1, who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion (TLIF).

About Bone Biologics

Bone Biologics (OTCQB: BBLG) is pursuing regenerative medicine for bone including undertaking groundbreaking work and building on unprecedented research on the NELL-1 molecule that has produced a significant number of studies and publications in peer reviewed scientific literature.

Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion. NELL-1 is a recombinant human protein growth factor that is essential for normal bone development.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
Latest news "Companies"
07:16aKARYOPHARM THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
07:16aLCI INDUSTRIES : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
07:16aTRANSDIGM : Reports Fiscal 2020 Third Quarter Results
PR
07:16aNEWS HIGHLIGHTS : Top Energy News of the Day
DJ
07:16aLantronix Announces Fall Investor Conference Schedule
GL
07:16aSCIENCE APPLICATIONS INTERNATIONAL : SAIC Schedules Second Quarter Fiscal Year 2021 Earnings Press Release and Conference Call for September 2 at 5 p.m. EDT
BU
07:15aR1 RCM INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
07:15aFRANK'S INTERNATIONAL N.V. : Results of Operations and Financial Condition (form 8-K)
AQ
Latest news "Companies"